trending Market Intelligence /marketintelligence/en/news-insights/trending/bhqiiww_ol0qvqbmljxpww2 content esgSubNav
In This List

Progenics, Par Pharma settle patent dispute over Relistor injection

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Progenics, Par Pharma settle patent dispute over Relistor injection

Progenics Pharmaceuticals Inc. settled a lawsuit against Par Pharmaceutical Inc., which is seeking to market a copycat version of the company's Relistor injection in the U.S.

Progenics and its partners Valeant Pharmaceuticals International Inc., Salix Pharmaceuticals Inc. and Pfizer Inc.'s Wyeth LLC, had said Par's generic methylnaltrexone bromide injection would infringe on two of their patents covering Relistor, a treatment for opioid-induced constipation.

The companies had filed a lawsuit against Par, which is owned by Endo International PLC, in the U.S. District Court for the District of New Jersey.

The settlement terminates the 30-month stay imposed by the U.S. Food and Drug Administration in relation to the approval of Par Pharmaceutical's abbreviated new drug application and allows it to market a generic version of the injection starting Sept. 30, 2030, or earlier under certain circumstances.